CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
| العنوان: | CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice |
|---|---|
| المؤلفون: | Luis Noronha, Fernando Camacho, Natasha Georgijev, Vincent Woo, Jennifer B. Rose, Maureen Clement, Wally Rapattoni, Matthew D. Culham, Shana Traina, Alan Bell, Michael A. Tsoukas, Harpreet S. Bajaj |
| المصدر: | Diabetes, Obesity & Metabolism |
| بيانات النشر: | Blackwell Publishing Ltd, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Canada, Drug-Related Side Effects and Adverse Reactions, Endocrinology, Diabetes and Metabolism, General Practice, effectiveness, 030209 endocrinology & metabolism, 030204 cardiovascular system & hematology, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Endocrinology, Randomized controlled trial, Weight loss, law, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, Electronic Health Records, Humans, Registries, Canagliflozin, Aged, business.industry, SGLT2 inhibitor, Original Articles, prospective, Middle Aged, medicine.disease, real‐world, Regimen, Blood pressure, Treatment Outcome, chemistry, Diabetes Mellitus, Type 2, Original Article, Female, Glycated hemoglobin, medicine.symptom, Canadian, business, Body mass index, medicine.drug |
| الوصف: | Aim There is limited information concerning the effects of canagliflozin (CANA), a sodium-glucose co-transporter 2 inhibitor (SGLT2i) in a real-world clinical setting in Canada. CanCARE is a 12-month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual clinical practice in Canada. Materials and methods SGLT2i-naive adult patients with type 2 diabetes mellitus (T2DM) (n = 527) on a stable antihyperglycemic agent (AHA) regimen with glycated hemoglobin (A1C) ≥ 7%, an estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73m2 , were initiated on CANA as part of their usual treatment approach, and were followed for a period of 12 months. The primary effectiveness objective was the mean change in HbA1c from baseline to 6 and 12 months. Results Significant improvement from baseline in mean HbA1c levels were observed at 6 months (-0.90%; 95% CI, -1.02, -0.78) and at 12 months (-1.04%; 95% CI, -1.15, -0.92), regardless of duration of diabetes or background AHA treatment regimen. Similarly, significant decreases in systolic blood pressure (-4.65 mm Hg); body weight (-3.24 kg), waist circumference (-2.91 cm) and body mass index (-1.15 kg/m2 ) were observed at 12 months. Additionally, 40.5% of patients achieved the double endpoint (≥0.5% HbA1c reduction and ≥ 3% weight loss), while 24.3% of patients achieved the triple composite endpoint (≥0.5% HbA1c reduction, ≥3% weight loss and ≥ 4 mm Hg systolic blood pressure reduction). No unexpected adverse events were reported. Conclusion CANA provided sustained clinically meaningful improvements in cardiometabolic parameters in this study in a real-world setting, confirming findings from randomized controlled trials. |
| اللغة: | English |
| تدمد: | 1463-1326 1462-8902 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6d2922cc28020f6568870e9b5574a2bTest http://europepmc.org/articles/PMC6667918Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....e6d2922cc28020f6568870e9b5574a2b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14631326 14628902 |
|---|